Biotech News

Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion (BMEA)Biomea FusionEarnings

Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 Enrollment ongoing in the Phase II COVALENT-212 clinical trial evaluating icovamenib in patients with

Related news

Biomea Fusion

Metabolic Disease Company Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity. Icovamenib Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes. COVALENT Program COVALENT-211 and...

Recent company news

Stock data

Close
0.59 USD
Market cap
99.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States